Radioimmunotherapy with an 211At‐labeled anti–tissue factor antibody protected by sodium ascorbate
Open Access
- 19 February 2021
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 112 (5) , 1975-1986
Abstract
Tissue factor (TF), the trigger protein of the extrinsic blood coagulation cascade, is abundantly expressed in various cancers including gastric cancer. Anti‐TF monoclonal antibodies (mAbs) capable of targeting cancers have been successfully applied to armed antibodies such as antibody‐drug conjugates (ADCs) and molecular imaging probes. We prepared an anti‐TF mAb, clone 1084, labeled with astatine‐211 (211At), as a promising alpha emitter for cancer treatment. Alpha particles are characterized by high linear energy transfer and a range of 50‐100 µm in tissue. Therefore, selective and efficient tumor accumulation of alpha emitters results in potent antitumor activities against cancer cells with minor effects on normal cells adjacent to the tumor. Although the 211At‐conjugated clone 1084 (211At‐anti‐TF mAb) was disrupted by an 211At‐induced radiochemical reaction, we demonstrated that astatinated anti‐TF mAbs eluted in 0.6% or 1.2% sodium ascorbate (SA) solution were protected from antibody denaturation, which contributed to the maintenance of cellular binding activities and cytocidal effects of this immunoconjugate. Although body weight loss was observed in mice administered a 1.2% SA solution, the loss was transient and the radioprotectant seemed to be tolerable in vivo. In a high TF–expressing gastric cancer xenograft model, 211At‐anti‐TF mAb in 1.2% SA exerted a significantly greater antitumor effect than nonprotected 211At‐anti‐TF mAb. Moreover, the antitumor activities of the protected immunoconjugate in gastric cancer xenograft models were dependent on the level of TF in cancer cells. These findings suggest the clinical availability of the radioprotectant and applicability of clone 1084 to 211At‐radioimmunotherapy.Keywords
Funding Information
- Japan Agency for Medical Research and Development (19cm0106237h0002)
- National Cancer Center (29‐A‐9, 30‐S‐4, 2020‐A‐9)
- RIKEN
- Japan Society for the Promotion of Science (16H06278)
This publication has 58 references indexed in Scilit:
- Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patientsBlood, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Direct Procedure for the Production of211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide ImmunoconjugateJournal of Nuclear Medicine, 2008
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft ModelsClinical Cancer Research, 2008
- Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu DiabodiesClinical Cancer Research, 2008
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- A Photon Counting Technique for Quantitatively Evaluating Progression of Peritoneal Tumor DisseminationCancer Research, 2006
- Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancerCancer Science, 2005
- Radiolysis of radioimmunoconjugates. Reduction in antigen-binding ability by α-particle radiationJournal of Labelled Compounds and Radiopharmaceuticals, 1995